當(dāng)前位置：   首頁 > 需求大廳

 >  特色服務(wù) 

 >  信息服務(wù) 

1.懸賞2013年1月1日之后NMPA不批準(zhǔn)的藥品信息 2.必須提供完整信息，以附件形式提交 3.核實(shí)后如果正確，每個獎勵100元 4.投稿時請隱藏提交 5.請勿在百度上直接搜索 6.需是藥智網(wǎng)未收集的數(shù)據(jù) 7.如有不清楚的地方，私信聯(lián)系   [更多]

1.懸賞2013年1月1日之后NMPA批準(zhǔn)的藥品信息 2.必須提供完整信息，以附件形式提交 3.核實(shí)后如果正確，每個獎勵30元 4.投稿時請隱藏提交 5.請勿在百度上直接搜索 6.需是藥智網(wǎng)未收集的數(shù)據(jù)   [更多]

1.懸賞2013年1月1日之后NMPA批準(zhǔn)的藥品注冊信息 2.必須提供完整信息，，以附件形式提交 3.核實(shí)后如果正確，每個獎勵30元 4.投稿時請隱藏提交 5.請勿在百度上直接搜索 6.需是藥智網(wǎng)未收集的數(shù)據(jù)   [更多]

需要USP 42 661/661.1/661.2 PDF版本   [更多]

1、Przemysl Chemiczny, 85(5), 349-350; 2006 2、Polymorphism of sodium valproate 【作 者】Mifsud, H.;Miguel, L.;Lavastre, V.;Maire, G. 【刊 名】Calorim. Anal. Therm. 【出版日期】1993 【卷 號】Vol.24 【頁 碼】309-312 3、Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC 4、[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group] 5、Ital J Gastroenterol. 1995 Sep;27(7):376-7. TUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effects. Leuschner U1, Guldutuna S, Bhatti S, Elze A, Imhof M, You T, Zimmer G. Author information 6、AJHYA2 American Journal of Hygiene. (Baltimore, MD) V.1-80, 1921-64. For publisher information, see AJEPAS. Volume(issue)/page/year: 76,209,1962   [更多]

1、Arzneimittelforschung. 1985;35(7A):1203-8. Ohashi S, Iwatani M, Hyakuna Y, Morioka Y. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. 2、Arzneimittelforschung. 1985;35(7A):1149-54. K Kawamura, K Watanabe, Y Kimura. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation 3、Gel formation of cefpodoxime proxetil 4、Gas chromatographic analysis of fosfomycin in plasma for pharmacokinetic analysis. GK Webster, RG Bell - Journal of AOAC International, 1999 - europepmc.org 5、Rydell N, Butler J, Balazs EA. Hyaluronic acid in synovial fluid.Ⅵ. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of the arthritis in track horses. Acta Vet Scand, 1970,11:139~146 6、Peyron JG, Balazs EA. Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joints. Pathol Biol, 1974, 22:731~736 7、Weiss C, Balazs EA, St Onge R, et al. Clinical studies of the intra-articular injection of Healon in the treatment of osteoarthritis of human knee. Semin Arhtritis Rheum, 1980, 11(Suppl 1):143~144 8、Punzi L, Schiavon F, Ramonda R, et al. Intra-articular hyaluronic acid in the treatment of inflammatory and non-inflammatory knee diffusions. Curr Ther Res, 1988, 43:643~647 9、Nolan JP, reducing Catheter Related Bacteraemia in Haemodialysis. Vascular Access Soc. 5th Int. Congress of Vascular Access Soc, Nice, 2007 10、Arzneimittelforschung. 1984;34(9):948-52. Iron derivatives of modified milk protein.   [更多]

1、Clinical Features and Molecular Genetics of HSD387 Deficiency and AKRlD1 Deficiency A case report of inborn errors of bile acid synthesis 2、3B-hydroxy-△5-C27 steroid dehydrogenase deficiency: a case report 3、Hallas G. Chem. and Ind. 1972,691 4、Chemical and biological characterization of iron-protein succinylate (ITF 282)' 5、Arzneimittelforschung. 1984;34(9):948-52. Iron derivatives of modified milk protein.   [更多]

1、targeting inhaled steroids 文獻(xiàn) 2、Minerva Dietol Gastroenterol. 1989 Jul-Sep;35(3):175-89. [A selective antimuscarinic agent: pirenzepine. Review of its pharmacologic and clinical properties]. [Article in Italian] Del Tacca M, Danesi R, Blandizzi C, Bernardini MC. 3、See 1 citation found by title matching your search: J Pharmacol. 1985;16 Suppl 2:145-69. [MI cholinergic receptors of gastric secretion: current status]. [Article in French]、 4、Carrigan PJ, Papp K, Schulz G, Venable T. Bioavailability of valproate from divalproex sodium tablets. Abbott Laboratories, North Chicago, IL (unpublished data). 5、MITOXANTRONE - MECHANISM OF ACTION, ANTITUMOR-ACTIVITY, PHARMACOKINETICS, EFFICACY IN THE TREATMENT OF SOLID TUMORS AND LYMPHOMAS, AND TOXICITY，文獻(xiàn) 6、American Journal of Kidney Diseases Volume 70, Issue 6, December 2017, Pages 737-751 KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)   [更多]

1、Nimesulide - a non-steroidal anti-inflammatory drug, a preferential cyclooxygenase-2 inhibitor 【出處】Vutreshni bolesti. 2000;32(1):33-6. 2、Bioequivalence study between two slow release batches ofindapamide SR 1.5 mg with different dissolution pro- files after repeated oral administration over 7 days in 12 healthy volunteers: a randomised double blind cross over study. Fulmer Hall, UK: Servier, 1993. Report No.: NP 910 3、Schiavi P, Jochemsen R, Hiley M, et al. Pharmacokinetics ofslow and immediate release formulations of indapamide after single oral administration under fasting conditions and after food, in healthy volunteers. Eur J Drug Metab Pharmacokinet 1996; Spe- cial Issue: 42 4、找一篇97年的政策法規(guī)文件，標(biāo)題：國家醫(yī)藥管理局國藥字（97）253號文件 5、Higuchi T, Murasaki M, Kamijima K. Clinical evaluation of duloxetine in the treatment of major depressive disorder. Jpn J Clin Psychopharmacol 2009;12:1613-1634   [更多]

具體要求： 1.懸賞2013年1月1日之后NMPA批準(zhǔn)的藥品信息 2.必須提供完整信息，以附件形式提交 3.核實(shí)后如果正確，每個獎勵30元 4.投稿時請隱藏提交 5.請勿在百度上直接搜索 6.需是藥智網(wǎng)未收集的數(shù)據(jù)   [更多]